KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells $71,904.30 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 2,685 shares of the company’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $26.78, for a total transaction of $71,904.30. Following the transaction, the insider owned 147,499 shares in the company, valued at $3,950,023.22. The trade was a 1.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Price Performance

KALV traded up $0.02 on Tuesday, hitting $26.81. 8,068,030 shares of the company were exchanged, compared to its average volume of 7,414,539. The company has a debt-to-equity ratio of 8.18, a quick ratio of 5.10 and a current ratio of 5.17. The business’s fifty day moving average is $21.74 and its 200 day moving average is $17.54. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $9.83 and a fifty-two week high of $26.85. The firm has a market capitalization of $1.43 billion, a P/E ratio of -7.75 and a beta of -0.12.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The firm had revenue of $39.17 million for the quarter, compared to analyst estimates of $39.03 million. As a group, sell-side analysts anticipate that KalVista Pharmaceuticals, Inc. will post -0.96 EPS for the current year.

Analyst Ratings Changes

KALV has been the topic of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 21st. JonesTrading lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 30th. Leerink Partners lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Citizens Jmp lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Finally, HC Wainwright lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $37.00 to $27.00 in a research report on Friday, May 1st. Three research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, KalVista Pharmaceuticals currently has an average rating of “Hold” and an average target price of $30.60.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Parallel Advisors LLC boosted its holdings in shares of KalVista Pharmaceuticals by 45.8% in the 1st quarter. Parallel Advisors LLC now owns 1,876 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 589 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of KalVista Pharmaceuticals by 5.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company’s stock valued at $165,000 after acquiring an additional 818 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after acquiring an additional 1,292 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of KalVista Pharmaceuticals by 2.8% during the 2nd quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock valued at $615,000 after acquiring an additional 1,458 shares in the last quarter. Finally, Royal Bank of Canada lifted its holdings in shares of KalVista Pharmaceuticals by 137.0% during the 1st quarter. Royal Bank of Canada now owns 2,917 shares of the specialty pharmaceutical company’s stock valued at $59,000 after acquiring an additional 1,686 shares in the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.